BiotechTube

DS-1001b

Phase 1Active
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Glioma

Conditions

Glioma

Trial Timeline

Jan 19, 2017 → Aug 31, 2026

NCT ID
NCT03030066

About DS-1001b

DS-1001b is a phase 1 stage product being developed by Daiichi Sankyo for Glioma. The current trial status is active. This product is registered under clinical trial identifier NCT03030066. Target conditions include Glioma.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (2)

NCT IDPhaseStatus
NCT04458272Phase 2Active
NCT03030066Phase 1Active

Competing Products

20 competing products in Glioma

See all competitors
ProductCompanyStageHype Score
TemozolomideNovocurePhase 1
28
Enzastaurin (LY317615) + CarboplatinEli LillyPhase 1
33
LY2157299 + LomustineEli LillyPhase 1
33
DS-1001bDaiichi SankyoPhase 2
52
Perampanel + Standard of CareEisaiPhase 1/2
41
Temozolomide and BevacizumabEisaiPhase 2
52
TemozolomideEisaiPhase 2
52
Gliadel Wafer + TemozolomideEisaiPhase 2
52
Palonosetron (PALO)EisaiPhase 2
52
Gliadel/Avastin/CPT-11EisaiPhase 2
52
Lenvatinib + BevacizumabEisaiPhase 2
52
Granisetron + OndansetronKyowa KirinPhase 2
52
Binimetinib 15 MGOno PharmaceuticalPhase 2
52
EnzastaurinEli LillyPhase 2
52
Pembrolizumab + Pemetrexed + AbemaciclibEli LillyPhase 1
33
LY2157299 + Radiation + TemozolomideEli LillyPhase 1/2
41
Abemaciclib + TemozolomideEli LillyPhase 2
52
DSP-0390Sumitomo PharmaPhase 1
33
DSP-0390Sumitomo PharmaPhase 1
33
ApatinibJiangsu Hengrui MedicinePhase 2
52

Other Products from Daiichi Sankyo

Olmesartan medoxomil + Olmesartan medoxomil/hydrochlorothiazide + HydrochlorothiazideApproved
85
OAC aloneApproved
85
olmesartan medoxomil + Placebo + losartan potassiumApproved
85
Prasugrel + ClopidogrelApproved
85
Diet+pravastatinApproved
85